December 29, 2025 01:45 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
CBI moves Supreme Court challenging Kuldeep Sengar's relief in Unnao rape case | Music under attack: Islamist mob attacks James concert with bricks, stones in Bangladesh, dozens hurt | Christmas vandalism sparks mass arrests in Raipur; Assam acts too with crackdown on 'religious intolerance' | BJP's VV Rajesh becomes Thiruvananthapuram Mayor after party topples Left's 45-year-rule in city corporation | ‘I can’t bear the pain’: Indian-origin father of three dies after 8-hour hospital wait in Canada hospital | Janhvi Kapoor, Kajal Aggarwal, Jaya Prada slam brutal lynching in Bangladesh, call out ‘selective outrage’ | Tarique Rahman returns to Bangladesh after 17 years | Shocking killing inside AMU campus: teacher shot dead during evening walk | Horror on Karnataka highway: sleeper bus bursts into flames after truck crash, 9 killed | PM Modi attends Christmas service at Delhi church, sends message of love and compassion
Chinese vaccine
Image: Unsplash

Pakistan says China's Sinopharm vaccine not recommended for people aged above 60

| @indiablooms | Feb 11, 2021, at 04:56 pm

The Chinese Sinopharm vaccine for Covid-19, which started being administered in Pakistan recently, is not recommended for people aged over 60, a top official said.

Speaking to reporters in Islamabad, Special Assistant to the Prime Minister on Health Dr Faisal Sultan was quoted as saying by Dawn News that the government's expert committee while considering the preliminary analysis of Sinopharm data had recommended that the vaccine be licensed for people aged 18-60 "at this stage".

"At this stage, the [committee] did not authorise the vaccine for people older than 60," he added.

When contacted by Dawn News about which vaccine would be used for people over 60 instead of Sinopharm's, Dr Sultan said the AstraZeneca vaccine would be used.

"When our Pakistani experts looked at the data, they were reasonably satisfied with the AstraZeneca data but felt that [based] on the presently available numbers for Sinopharm, the data did not justify its usage for those aged over 60," he said.

"The Chinese have also reiterated this restriction," he added.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.